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a b s t r a c t
Posterior circulation stroke accounts for approximately 20% of all ischaemic strokes. Acute
basilar artery occlusion (BAO) is one of the most severe conditions, it is associated with death
or major disability in more than three quarters of the cases, and its optimal management
remains unestablished. Currently, the treatment is based primarily upon consensus, the
clinical practice varies widely, and the actual beneﬁt of mechanical thrombectomy has to be
fully estimated. Although the recent years have profoundly revolutionized and improved the
stroke care, many questions still remain unanswered and will represent the challenges of
the next future.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnnsWe greatly appreciated the article by Wyszomirski et al. who
systematically reviewed the evidence about the efﬁcacy of the
intra-venous (IV) and intra-arterial (IA) thrombolysis with
recombinant tissue plasminogen activator (rt-PA) and me-
chanical thrombectomy (MT) in the treatment of acute basilar
artery occlusion (BAO) [1].
The ﬁrst striking issue raised by the pooled analysis is the
very low quality of the currently available data. Among the 31
included records, there was no single randomized controlled
trial: all studies were observational, mostly retrospective and
single centre-based, with a small number of patients in each
arm. Hence, all the limits of the uncontrolled series should be
taken into account: the reasons underpinning the choice of a
speciﬁc option are more complex than can be captured within
the aim of a stroke registry, and selection bias could act as a
meaningful confounding factor. In addition, multivariable
analyses can never completely adjust for unmeasured
outcome-related variables, systematic differences in deﬁni-
tions and protocols, and imbalances between treatment
groups according to baseline patients characteristics, time
onset-to-treatment, or method and timing of diagnosis and
follow up. It is also noteworthy considering that only three
reports described ﬁndings from the IV rt-PA therapy, althoughDOI of original article: https://doi.org/10.1016/j.pjnns.
2017.07.012intravenous ﬁbrinolysis is widely accessible and easy to
perform, and represents the standard of care in acute
ischaemic stroke.
Second, the meta-analysis highlighted how unfavourable is
the prognosis of patients presenting with posterior circulation
stroke. Despite the advancement in stroke care and the
availability of several treatment strategies, acute BAO is still
associated with death or major disability in more than three
quarters of the cases.
Third, a strong relationship exists between revasculariza-
tion and prognosis: although higher recanalization rate does
not automatically translate into better clinical outcome, there
is hardly any chance of favourable recovery if recanalization
does not occur [2]. Bearing in mind that early recanalization is
substantial, the rt-PA alone is more likely to fail in the presence
of large clot burden, and the endovascular intervention
represents the most effective method of artery recanalization,
it is reasonable thinking that MT could be the most effective
treatment of patients with acute BAO, as suggested by the
pooled integrated analysis [1]. To this respect, neuro-thromb-
ectomy has undoubtedly signed the dawn of a new era and
represented the greatest advance in the management of acute
ischaemic stroke since the deﬁnitive approval of the intrave-
nous tissue-type plasminogen activator in 1996. However, all
trials investigating the efﬁcacy and safety of the endovascular
strategy have mainly involved anterior circulation proximal
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patients with basilar artery involvement since the several
factors distinguishing BAO from middle cerebral or internal
carotid artery disease, as the severity of the deﬁcit, the high
poor-outcome rate, the collateral blood-ﬂow supply and the
time-window for treatment.
The recent years have profoundly revolutionized and
improved the stroke care [3–9]; nonetheless, many questions
still remain unanswered and will represent the challenges of
the next future. To date, the management of acute ischaemic
stroke due to BAO is based primarily on consensus, empirical
cases series and observational data, the clinical practice varies
widely, and the actual beneﬁt of the endovascular strategies
has to be estimated exactly. The Acute Basilar Artery
Occlusion: Endovascular Interventions versus Standard Medi-
cal Treatment (BEST) Trial (ClinicalTrials.gov number,
NCT02441556) [10] and the Basilar Artery International
Cooperation Study (BASICS) (NCT01717755) [11] are the only
on-going, actively recruiting, randomized clinical trials aimed
to evaluate the efﬁcacy and safety of the standard medical
therapy (IV rt-PA) plus the endovascular treatment (thrombus
retraction, aspiration or use of a stent retriever device) (BEST
trial) or the IA thrombolysis (BASICS) versus the standard
medical therapy alone in patients with BAO presenting within
8 and 6 h from the estimated occlusion time, respectively.
These trials will recruited more than 600 patients until January
2020 (BASIC) and March 2018 (BEST trial), and their ﬁndings are
expected to provide novel and evidence-based insights into
the optimal approach for acute BAO treatment.
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